| dbo:abstract
|
- باسيريوتيد (بالإنجليزية: Pasireotide) هو دواء يُستعمل في علاج:
* مرض كوشينج المعتمد على النخامية (منذ 14 ديسمبر 2012) (ar)
- Le pasiréotide est une molécule analogue synthétique de la somatostatine, inhibant l'action de l'hormone de croissance. (fr)
- Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. The most common side effects include hyperglycaemia (high blood sugar levels), diabetes, diarrhoea, abdominal pain (stomach ache), nausea (feeling sick), cholelithiasis (gallstones), injection site reactions, and tiredness. Pasireotide was approved for Cushing's disease by the European Medicines Agency (EMA) in April 2012 and by the U.S. Food and Drug Administration (FDA) in December 2012. Pasireotide LAR (the long-acting-release formulation) was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMA in September 2014. (en)
- Il pasireotide è un peptide, analogo della somatostatina, caratterizzato da un'affinità per il recettore della somatostatina 5 quaranta volte maggiore dell'ormone endogeno e cinque volte maggiore rispetto agli altri analoghi. È un farmaco orfano sviluppato da Novartis, (Brand name: SIGNIFOR), studiato per la terapia della malattia di Cushing. Il farmaco ha mostrato un potenziale effetto terapeutico in uno studio clinico del 2010 condotto su 162 pazienti trattati con di parireotide (dosaggio di 2x 600 µg o 2x 900 µg al giorno). L'efficacia del trattamento è stata valutata con il dosaggio cortisolo libero urinario dopo sei mesi dal trattamento, dimostrandone una riduzione massima pari al 47,9%, unito a un miglioramento clinico in termini di pressione arteriosa, colesterolemia e perdita di peso. (it)
- パシレオチド（Pasireotide）は、米国、欧州、日本において、外科的治療に失敗した、あるいは不適格な患者のクッシング病の治療薬として承認されている希少疾病用医薬品である。パシレオチドは、他のソマトスタチンアナログと比較して、への親和性が40倍も高いソマトスタチンアナログである。筋肉内注射で用いられる。 主な副作用には、高血糖、糖尿病、下痢、腹痛（胃痛）、吐き気、胆石症、注射部位反応、疲労感などがある。 (ja)
- Pasireotide é um fármaco da Novartis de marca comercial Signifor. Foi aprovado para ser utilizado no tratamento da doença de Cushing pelo FDA em dezembro de 2012. Nos estudos clínicos de fase III mostrou que a maioria dos pacientes testados conseguiu reduzir os níveis de cortisol na urina. (pt)
|
| dbo:alternativeName
|
- Signifor, Signifor LAR (en)
|
| dbo:casNumber
| |
| dbo:chEBI
| |
| dbo:drugbank
| |
| dbo:fdaUniiCode
| |
| dbo:kegg
| |
| dbo:pubchem
| |
| dbo:thumbnail
| |
| dbo:wikiPageExternalLink
| |
| dbo:wikiPageID
| |
| dbo:wikiPageLength
|
- 7211 (xsd:nonNegativeInteger)
|
| dbo:wikiPageRevisionID
| |
| dbo:wikiPageWikiLink
| |
| dbp:atcPrefix
| |
| dbp:atcSuffix
| |
| dbp:c
| |
| dbp:casNumber
| |
| dbp:chebi
| |
| dbp:chemspiderid
| |
| dbp:dailymedid
| |
| dbp:drugbank
| |
| dbp:h
| |
| dbp:iupacName
|
- [-9--3-benzyl-12--2,5,8,11,14,17-hexaoxo-15-phenyl-6-[methyl]-1,4,7,10,13,16-hexazabicyclo[16.3.0]henicosan-20-yl] N-carbamate (en)
|
| dbp:iupharLigand
| |
| dbp:kegg
| |
| dbp:legalEu
| |
| dbp:legalStatus
| |
| dbp:legalUk
| |
| dbp:legalUs
| |
| dbp:licenceEu
| |
| dbp:n
| |
| dbp:o
| |
| dbp:pregnancyAu
| |
| dbp:pregnancyUs
| |
| dbp:pubchem
| |
| dbp:routesOfAdministration
| |
| dbp:smiles
| |
| dbp:stdinchi
| |
| dbp:stdinchikey
|
- VMZMNAABQBOLAK-DBILLSOUSA-N (en)
|
| dbp:synonyms
| |
| dbp:tradename
|
- Signifor, Signifor LAR (en)
|
| dbp:unii
| |
| dbp:verifiedfields
| |
| dbp:verifiedrevid
| |
| dbp:watchedfields
| |
| dbp:wikiPageUsesTemplate
| |
| dcterms:subject
| |
| gold:hypernym
| |
| rdf:type
| |
| rdfs:comment
|
- باسيريوتيد (بالإنجليزية: Pasireotide) هو دواء يُستعمل في علاج:
* مرض كوشينج المعتمد على النخامية (منذ 14 ديسمبر 2012) (ar)
- Le pasiréotide est une molécule analogue synthétique de la somatostatine, inhibant l'action de l'hormone de croissance. (fr)
- パシレオチド（Pasireotide）は、米国、欧州、日本において、外科的治療に失敗した、あるいは不適格な患者のクッシング病の治療薬として承認されている希少疾病用医薬品である。パシレオチドは、他のソマトスタチンアナログと比較して、への親和性が40倍も高いソマトスタチンアナログである。筋肉内注射で用いられる。 主な副作用には、高血糖、糖尿病、下痢、腹痛（胃痛）、吐き気、胆石症、注射部位反応、疲労感などがある。 (ja)
- Pasireotide é um fármaco da Novartis de marca comercial Signifor. Foi aprovado para ser utilizado no tratamento da doença de Cushing pelo FDA em dezembro de 2012. Nos estudos clínicos de fase III mostrou que a maioria dos pacientes testados conseguiu reduzir os níveis de cortisol na urina. (pt)
- Pasireotide, sold under the brand name Signifor, is an orphan drug approved in the United States and the European Union for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy. It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. Pasireotide was approved for Cushing's disease by the European Medicines Agency (EMA) in April 2012 and by the U.S. Food and Drug Administration (FDA) in December 2012. (en)
- Il pasireotide è un peptide, analogo della somatostatina, caratterizzato da un'affinità per il recettore della somatostatina 5 quaranta volte maggiore dell'ormone endogeno e cinque volte maggiore rispetto agli altri analoghi. È un farmaco orfano sviluppato da Novartis, (Brand name: SIGNIFOR), studiato per la terapia della malattia di Cushing. (it)
|
| rdfs:label
|
- باسيريوتيد (ar)
- Pasiréotide (fr)
- Pasireotide (it)
- パシレオチド (ja)
- Pasireotide (en)
- Pasireotide (pt)
|
| owl:sameAs
| |
| prov:wasDerivedFrom
| |
| foaf:depiction
| |
| foaf:isPrimaryTopicOf
| |
| is dbo:wikiPageRedirects
of | |
| is dbo:wikiPageWikiLink
of | |
| is foaf:primaryTopic
of | |
